NLRP3 and diabetic cardiomyopathy: Inflammation and priming of the NLRP3 inflammasome are thought to play an important role in the development of heart failure.71–73 Furthermore, the SGLT2i dapagliflozin reduces NLRP3 activation and diabetic cardiomyopathy in a mouse model of type 2 diabetes.74 Our group has also recently shown that empagliflozin prevents worsening of heart failure in nondiabetic mice,17 and that empagliflozin also prevents NLRP3 activation in a calcium-dependent manner.18 Taken together, these results suggest that the SGLT2is have a direct suppressive effect on NLRP3 activation in the heart.